SetPoint Medical Received FDA Approval for Novel Neuroimmune Modulation Therapy for Rheumatoid Arthritis
On July 31, 2025, SetPoint Medical, a company focused on developing therapies for individuals with chronic autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) approved its SetPoint System. This groundbreaking device is the first neuroimmune modulation system designed to treat adults with moderate-to-severe rheumatoid arthritis (RA) who have not responded adequately to or cannot tolerate current advanced RA treatments, including biologics and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs).
“The approval of ...